Active Ingredient History

  • Now
Basimglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications.   Wikipedia

  • SMILES: Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1c3ccc(F)cc3
  • Mol. Mass: 325.77
  • ALogP: 4.08
  • ChEMBL Molecule:
More Chemistry
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1h-imidazol-4-ylethynyl)pyridine | basimglurant | rg-7090 | ro4917523 | ro-4917523


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue